Literature DB >> 12917485

Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Christos Sotiriou1, Soek-Ying Neo, Lisa M McShane, Edward L Korn, Philip M Long, Amir Jazaeri, Philippe Martiat, Steve B Fox, Adrian L Harris, Edison T Liu.   

Abstract

Comprehensive gene expression patterns generated from cDNA microarrays were correlated with detailed clinico-pathological characteristics and clinical outcome in an unselected group of 99 node-negative and node-positive breast cancer patients. Gene expression patterns were found to be strongly associated with estrogen receptor (ER) status and moderately associated with grade, but not associated with menopausal status, nodal status, or tumor size. Hierarchical cluster analysis segregated the tumors into two main groups based on their ER status, which correlated well with basal and luminal characteristics. Cox proportional hazards regression analysis identified 16 genes that were significantly associated with relapse-free survival at a stringent significance level of 0.001 to account for multiple comparisons. Of 231 genes previously reported by others [van't Veer, L. J., et al. (2002) Nature 415, 530-536] as being associated with survival, 93 probe elements overlapped with the set of 7,650 probe elements represented on the arrays used in this study. Hierarchical cluster analysis based on the set of 93 probe elements segregated our population into two distinct subgroups with different relapse-free survival (P < 0.03). The number of these 93 probe elements showing significant univariate association with relapse-free survival (P < 0.05) in the present study was 14, representing 11 unique genes. Genes involved in cell cycle, DNA replication, and chromosomal stability were consistently elevated in the various poor prognostic groups. In addition, glutathione S-transferase M3 emerged as an important survival marker in both studies. When taken together with other array studies, our results highlight the consistent biological and clinical associations with gene expression profiles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917485      PMCID: PMC193572          DOI: 10.1073/pnas.1732912100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  MCM proteins in DNA replication.

Authors:  B K Tye
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays.

Authors:  Christos Sotiriou; Chand Khanna; Amir A Jazaeri; David Petersen; Edison T Liu
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  GATA-3 is expressed in association with estrogen receptor in breast cancer.

Authors:  R V Hoch; D A Thompson; R J Baker; R J Weigel
Journal:  Int J Cancer       Date:  1999-04-20       Impact factor: 7.396

5.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type.

Authors:  F Ugolini; E Charafe-Jauffret; V J Bardou; J Geneix; J Adélaïde; F Labat-Moleur; F Penault-Llorca; M Longy; J Jacquemier; D Birnbaum; M J Pébusque
Journal:  Oncogene       Date:  2001-09-13       Impact factor: 9.867

7.  Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway.

Authors:  D Prévôt; A P Morel; T Voeltzel; M C Rostan; R Rimokh; J P Magaud; L Corbo
Journal:  J Biol Chem       Date:  2001-01-02       Impact factor: 5.157

8.  Predicting the clinical status of human breast cancer by using gene expression profiles.

Authors:  M West; C Blanchette; H Dressman; E Huang; S Ishida; R Spang; H Zuzan; J A Olson; J R Marks; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

9.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

Authors:  S Gruvberger; M Ringnér; Y Chen; S Panavally; L H Saal; M Fernö; C Peterson; P S Meltzer
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

10.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

View more
  660 in total

1.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Authors:  Lisa A Carey; Hope S Rugo; P Kelly Marcom; Erica L Mayer; Francisco J Esteva; Cynthia X Ma; Minetta C Liu; Anna Maria Storniolo; Mothaffar F Rimawi; Andres Forero-Torres; Antonio C Wolff; Timothy J Hobday; Anastasia Ivanova; Wing-Keung Chiu; Madlyn Ferraro; Emily Burrows; Philip S Bernard; Katherine A Hoadley; Charles M Perou; Eric P Winer
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

3.  Expression of the novel human gene, UBE2Q1, in breast tumors.

Authors:  Atefeh Seghatoleslam; Mohsen Nikseresht; Sayed Mohammad Shafiee; Ahmad Monabati; Mohammad Mehdi Namavari; Abdolrassul Talei; Akbar Safaei; Ali Akbar Owji
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

4.  Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.

Authors:  Marie-Liesse Asselin-Labat; Kate D Sutherland; François Vaillant; David E Gyorki; Di Wu; Sheridan Holroyd; Kelsey Breslin; Teresa Ward; Wei Shi; Mary L Bath; Siddhartha Deb; Stephen B Fox; Gordon K Smyth; Geoffrey J Lindeman; Jane E Visvader
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

Review 5.  Role of gene expression arrays in sarcomas.

Authors:  Keith M Skubitz; Amy P N Skubitz
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

Review 6.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 7.  Cancer stem cells: a novel paradigm for cancer prevention and treatment.

Authors:  Dharmalingam Subramaniam; Satish Ramalingam; Courtney W Houchen; Shrikant Anant
Journal:  Mini Rev Med Chem       Date:  2010-05       Impact factor: 3.862

8.  A molecularly targeted theranostic probe for ovarian cancer.

Authors:  Wenxue Chen; Rizia Bardhan; Marc Bartels; Carlos Perez-Torres; Robia G Pautler; Naomi J Halas; Amit Joshi
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

9.  Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors.

Authors:  Fatima Cardoso
Journal:  Breast Care (Basel)       Date:  2008-12-02       Impact factor: 2.860

Review 10.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.